Article thumbnail

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma

By A Greystoke, J P B O'Connor, K Linton, M B Taylor, J Cummings, T Ward, F Maders, A Hughes, M Ranson, T M Illidge, J Radford and C Dive
Topics: Molecular Diagnostics
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:3049589
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2011). Cancer Inst 98: 580–598 Circulating biomarkers in lymphoma patients A Greystoke et al
  2. (2009). Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.
  3. (2007). Elevated levels of interleukin-1beta-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction.
  4. (2001). Level of Flt3-ligand in plasma: a possible new bio-indicator for radiation-induced aplasia.